U.S. markets closed

Monopar Therapeutics Inc. (MNPR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.28+0.09 (+1.73%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close5.19
Open5.13
Bid5.10 x 1300
Ask5.46 x 1100
Day's Range5.13 - 5.41
52 Week Range4.28 - 17.01
Volume7,572
Avg. Volume250,445
Market Cap66.369M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer

    Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could potentially identify breast cancers with uPA overexpression and monitor uPA activity during treatment using PET imaging. uPA is an established biomarker in current breast cancer clinical practice guidelines, and its presence is used to select appropriate drug treatment. Monopar has a panel of proprietary antibodies and antibody fragments to uPA and its receptor uPAR (such as MNPR-101). The company's antibody fragment (ATN-291 F(ab')2) conjugated to a copper radiotracer enabled rapid PET visualization of tumors with uPA overexpression in a human breast cancer model in mice. Price Action: MNPR shares are up 12.3% at $6.47 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaBioNTech Stock Is Trading Higher On First Annual Profit; Raises 2021 Production Target For COVID-19 Shots To 2.5B DosesFDA Accepts AbbVie's Atogepant US Review Application For Migraine© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth
    Simply Wall St.

    Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%
    Zacks

    Monopar Therapeutics (MNPR) Jumps: Stock Rises 7.4%

    Monopar Therapeutics (MNPR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.